Cargando…

QiShenYiQi pills, a Chinese patent medicine, increase bioavailability of atorvastatin by inhibiting Mrp2 expression in rats

CONTEXT: Atorvastatin (ATV) and QiShenYiQi pills (QSYQ), a Chinese patent medicine, are often co-prescribed to Chinese cardiovascular patients. The effects of QSYQ on the pharmacokinetics of ATV have not been studied. OBJECTIVE: We investigated the influence of QSYQ on the pharmacokinetics of ATV an...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Congyang, Li, Yajing, Li, Xiao, Meng, Lu, Fu, Ran, Wang, Xiaonan, Li, Ying, Ma, Yinling, Dong, Zhanjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745373/
https://www.ncbi.nlm.nih.gov/pubmed/35001796
http://dx.doi.org/10.1080/13880209.2021.2021949
_version_ 1784630329648087040
author Ding, Congyang
Li, Yajing
Li, Xiao
Meng, Lu
Fu, Ran
Wang, Xiaonan
Li, Ying
Ma, Yinling
Dong, Zhanjun
author_facet Ding, Congyang
Li, Yajing
Li, Xiao
Meng, Lu
Fu, Ran
Wang, Xiaonan
Li, Ying
Ma, Yinling
Dong, Zhanjun
author_sort Ding, Congyang
collection PubMed
description CONTEXT: Atorvastatin (ATV) and QiShenYiQi pills (QSYQ), a Chinese patent medicine, are often co-prescribed to Chinese cardiovascular patients. The effects of QSYQ on the pharmacokinetics of ATV have not been studied. OBJECTIVE: We investigated the influence of QSYQ on the pharmacokinetics of ATV and its metabolites upon oral or intravenous administration of ATV to rats. MATERIALS AND METHODS: Sprague-Dawley rats (n = 5/group) were pre-treated with oral QSYQ (675 mg/kg) or vehicle control for 7 days and then orally administrated ATV (10 mg/kg) or intravenously administrated ATV (2 mg/kg). Serum concentrations of ATV and metabolites were determined by ultra-high performance liquid chromatography tandem mass spectrometry. Expression of metabolic enzymes and transporters in jejunum and ileum were measured by quantitative real-time PCR and Western blot. RESULTS: QSYQ resulted in an increase of AUC(0-12 h) of ATV from 226.67 ± 42.11 to 408.70 ± 161.75 ng/mL/h and of C(max) of ATV from 101.46 ± 26.18 to 198.00 ± 51.69 ng/mL and in an increased of para-hydroxy atorvastatin from 9.07 ± 6.20 to 23.10 ± 8.70 ng/mL in rats administered ATV orally. No change was observed in rats treated intravenously. The expression of multidrug resistance-associated protein 2 mRNA and protein decreased in ileum, and the mRNA of P-glycoprotein decreased in jejunum, though no change in protein expression was found. DISCUSSION AND CONCLUSIONS: QSYQ increased bioavailability of ATV administered orally through inhibiting the expression of Mrp2 in ileum. Clinicians should pay close attention to potential drug-drug interactions between ATV and QSYQ.
format Online
Article
Text
id pubmed-8745373
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-87453732022-01-11 QiShenYiQi pills, a Chinese patent medicine, increase bioavailability of atorvastatin by inhibiting Mrp2 expression in rats Ding, Congyang Li, Yajing Li, Xiao Meng, Lu Fu, Ran Wang, Xiaonan Li, Ying Ma, Yinling Dong, Zhanjun Pharm Biol Research Article CONTEXT: Atorvastatin (ATV) and QiShenYiQi pills (QSYQ), a Chinese patent medicine, are often co-prescribed to Chinese cardiovascular patients. The effects of QSYQ on the pharmacokinetics of ATV have not been studied. OBJECTIVE: We investigated the influence of QSYQ on the pharmacokinetics of ATV and its metabolites upon oral or intravenous administration of ATV to rats. MATERIALS AND METHODS: Sprague-Dawley rats (n = 5/group) were pre-treated with oral QSYQ (675 mg/kg) or vehicle control for 7 days and then orally administrated ATV (10 mg/kg) or intravenously administrated ATV (2 mg/kg). Serum concentrations of ATV and metabolites were determined by ultra-high performance liquid chromatography tandem mass spectrometry. Expression of metabolic enzymes and transporters in jejunum and ileum were measured by quantitative real-time PCR and Western blot. RESULTS: QSYQ resulted in an increase of AUC(0-12 h) of ATV from 226.67 ± 42.11 to 408.70 ± 161.75 ng/mL/h and of C(max) of ATV from 101.46 ± 26.18 to 198.00 ± 51.69 ng/mL and in an increased of para-hydroxy atorvastatin from 9.07 ± 6.20 to 23.10 ± 8.70 ng/mL in rats administered ATV orally. No change was observed in rats treated intravenously. The expression of multidrug resistance-associated protein 2 mRNA and protein decreased in ileum, and the mRNA of P-glycoprotein decreased in jejunum, though no change in protein expression was found. DISCUSSION AND CONCLUSIONS: QSYQ increased bioavailability of ATV administered orally through inhibiting the expression of Mrp2 in ileum. Clinicians should pay close attention to potential drug-drug interactions between ATV and QSYQ. Taylor & Francis 2022-01-08 /pmc/articles/PMC8745373/ /pubmed/35001796 http://dx.doi.org/10.1080/13880209.2021.2021949 Text en © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Ding, Congyang
Li, Yajing
Li, Xiao
Meng, Lu
Fu, Ran
Wang, Xiaonan
Li, Ying
Ma, Yinling
Dong, Zhanjun
QiShenYiQi pills, a Chinese patent medicine, increase bioavailability of atorvastatin by inhibiting Mrp2 expression in rats
title QiShenYiQi pills, a Chinese patent medicine, increase bioavailability of atorvastatin by inhibiting Mrp2 expression in rats
title_full QiShenYiQi pills, a Chinese patent medicine, increase bioavailability of atorvastatin by inhibiting Mrp2 expression in rats
title_fullStr QiShenYiQi pills, a Chinese patent medicine, increase bioavailability of atorvastatin by inhibiting Mrp2 expression in rats
title_full_unstemmed QiShenYiQi pills, a Chinese patent medicine, increase bioavailability of atorvastatin by inhibiting Mrp2 expression in rats
title_short QiShenYiQi pills, a Chinese patent medicine, increase bioavailability of atorvastatin by inhibiting Mrp2 expression in rats
title_sort qishenyiqi pills, a chinese patent medicine, increase bioavailability of atorvastatin by inhibiting mrp2 expression in rats
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745373/
https://www.ncbi.nlm.nih.gov/pubmed/35001796
http://dx.doi.org/10.1080/13880209.2021.2021949
work_keys_str_mv AT dingcongyang qishenyiqipillsachinesepatentmedicineincreasebioavailabilityofatorvastatinbyinhibitingmrp2expressioninrats
AT liyajing qishenyiqipillsachinesepatentmedicineincreasebioavailabilityofatorvastatinbyinhibitingmrp2expressioninrats
AT lixiao qishenyiqipillsachinesepatentmedicineincreasebioavailabilityofatorvastatinbyinhibitingmrp2expressioninrats
AT menglu qishenyiqipillsachinesepatentmedicineincreasebioavailabilityofatorvastatinbyinhibitingmrp2expressioninrats
AT furan qishenyiqipillsachinesepatentmedicineincreasebioavailabilityofatorvastatinbyinhibitingmrp2expressioninrats
AT wangxiaonan qishenyiqipillsachinesepatentmedicineincreasebioavailabilityofatorvastatinbyinhibitingmrp2expressioninrats
AT liying qishenyiqipillsachinesepatentmedicineincreasebioavailabilityofatorvastatinbyinhibitingmrp2expressioninrats
AT mayinling qishenyiqipillsachinesepatentmedicineincreasebioavailabilityofatorvastatinbyinhibitingmrp2expressioninrats
AT dongzhanjun qishenyiqipillsachinesepatentmedicineincreasebioavailabilityofatorvastatinbyinhibitingmrp2expressioninrats